Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STS101 in acute migraine
NCT04940390Phase 3Completed
- Start
- Jun 2021
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in migraine comparing STS101 with Placebo (2 arms). Primary endpoints: Percentage of Subjects With Freedom From Migraine Headache Pain at 2 Hours Post Dose and Percentage of Subjects With Freedom From Most-Bothersome Symptom at 2 Hours Post Dose. Started Jun 2021; status: completed.
02
Drugs
dihydroergotamine
03
Conditions
migraine
Beyond the preview
Go deeper on NCT04940390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04940390.